{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:44Z","timestamp":1787962304290,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathioprine (AZA) or mercaptopurine (MP) therapy within 3 months of treatment initiation because of adverse drug reactions. Of these side-effects, about half are because of hepatotoxicity. The aim of this study was to validate and (subsequently) optimize a previously reported predictive algorithm for thiopurine-associated hepatotoxicity by increasing the number of patients with IBD benefitting from conventional thiopurine therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This multicenter observational study included consecutive thiopurine-naive patients with IBD who received AZA or MP treatment. The primary outcome was hepatotoxicity within 12 weeks. The patients with and without hepatotoxicity were compared. Four determinants, namely, age, sex, body mass index (BMI), and 6-methylmercaptopurine ribonucleotide concentrations 1 week after treatment initiation (T = 1) were used to validate and optimize 2 (1 dichotomous and 1 continuous) algorithms using multivariable logistic regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 229 patients, 21 (9%) developed hepatotoxicity and 93% of the patients received MP with a median dose of 0.7 mg\/kg (95% confidence interval 0.3\u20131.4 mg\/kg). A difference in BMI was found between with and without hepatotoxicity groups (median 27.6 versus 24.2, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.022). Specificities of 68% (Algorithm 1) and 77% (Algorithm 2) and sensitivities of 56% (Algorithm 1) and 50% (Algorithm 2) were obtained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Both algorithms demonstrated limited predictive accuracy for thiopurine-induced hepatotoxicity in the validation cohort. Relevant factors contributing to this outcome were changes in thiopurine prescription behavior over time, with more MP prescriptions at relatively lower dosages of MP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001031","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T23:01:52Z","timestamp":1662591712000},"page":"747-754","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Predictive Algorithm for Thiopurine-Induced Hepatotoxicity in Inflammatory Bowel Disease Patients"],"prefix":"10.1097","volume":"44","author":[{"given":"Sofia A. W.","family":"van Moorsel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands;"},{"name":"Department of Clinical Pharmacy, Bernhoven Hospital, Uden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie S.","family":"Deben","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Clinical Pharmacology and Toxicology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob H.","family":"Creemers","sequence":"additional","affiliation":[{"name":"Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen\/Heerlen, the Netherlands;"},{"name":"Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Winkens","sequence":"additional","affiliation":[{"name":"Department of Methodology and Statistics, Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bus","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Laurentius Hospital, Roermond, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J.","family":"Pierik","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne K. H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"van Bodegraven","sequence":"additional","affiliation":[{"name":"Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen\/Heerlen, the Netherlands;"},{"name":"Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Wong","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Clinical Pharmacology and Toxicology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.gastro.2018.11.039","article-title":"Thiopurine therapy in inflammatory bowel diseases: making new friends should not mean losing old ones","volume":"156","author":"de Boer","year":"2019","journal-title":"Gastroenterology"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40262-018-0639-4","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory bowel disease","volume":"57","author":"Derijks","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.16777","article-title":"Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study","volume":"55","author":"Thomsen","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ncpgasthep1000","article-title":"Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD","volume":"4","author":"de Boer","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13879","article-title":"Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease","volume":"45","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1572-0241.2007.01187.x","article-title":"Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review","volume":"102","author":"Gisbert","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2036.2009.04132.x","article-title":"Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease","volume":"31","author":"Bermejo","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/17425255.2021.2029406","article-title":"Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease","volume":"17","author":"Deben","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","article-title":"Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy","volume":"26","author":"Derijks","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/ibd\/izy163","article-title":"Nonsynonymous polymorphism in guanine monophosphate synthetase is a risk factor for unfavorable thiopurine metabolite ratios in patients with inflammatory bowel disease","volume":"24","author":"Roberts","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1097\/MIB.0000000000001163","article-title":"More dose-dependent side effects with mercaptopurine over azathioprine in IBD treatment due to relatively higher dosing","volume":"23","author":"Broekman","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","article-title":"Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC","volume":"44","author":"Dervieux","year":"1998","journal-title":"Clin Chem."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"595219","DOI":"10.3389\/fphar.2020.595219","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2020","journal-title":"Front Pharmacol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FTD.0000000000000312","article-title":"Clinical value of mercaptopurine after failing azathioprine therapy in patients with inflammatory bowel disease","volume":"38","author":"Meijer","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/j.1572-0241.2007.01515.x","article-title":"Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients","volume":"102","author":"Shaye","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/FTD.0000000000000213","article-title":"Routinely established skewed thiopurine metabolism leads to a strikingly high rate of early therapeutic failure in patients with inflammatory bowel disease","volume":"37","author":"Kreijne","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.15402","article-title":"Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment","volume":"50","author":"Kreijne","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v22.i40.9012","article-title":"Efficacy of thioguanine treatment in inflammatory bowel disease: a systematic review","volume":"22","author":"Meijer","year":"2016","journal-title":"World J Gastroenterol."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/138920009790711887","article-title":"On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance","volume":"10","author":"Van Asseldonk","year":"2009","journal-title":"Curr Drug Metab."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:15:53Z","timestamp":1748970953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001031","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"2022-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}